Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Supreme Court Declines Review Of False Claims Act, PCSK9, Hep C Patents

Executive Summary

Gilead disputed Campie FCA decision, Amgen challenged Repatha ruling, and Merck challenged "unclean hands" defense against damages. Patent and Trademark Office wants court to determine if its attorneys' fees should be covered by patent applicants challenging its decisions.

You may also be interested in...



Can Government Petition PTAB To Review Patents? Supreme Court Seems Skeptical

Justice Sotoymayor suggests 'the deck is stacked' against private citizen who is dragged by government into AIA's post-grant review proceedings. Court denies petition seeking to revive Maryland's anti-price gouging law.

Federal Circuit Tosses Diagnostic Patent, Spurring Biopharma Calls For Congressional Action

A divided panel finds Athena Diagnostics' patent on method to diagnose myasthenia gravis is invalid; in dissent, Judge Newman cites industry concerns that the decision will deter development of new diagnostic methods.

Product Liability Defense Favored By Industry Appears To Have Supreme Court Support

US FDA's rejection of Merck's proposed Fosamax label warning preempts state-law tort suits, several Justices appear to conclude, as Kagan and Sotomayor question whether the proposal focused on the right risk.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS124512

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel